Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab
- Status
- UNKNOWN
- Phase
- PHASE2
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Novel Treatment Option for Neuropathic Pain
- Status
- COMPLETED
- Phase
- PHASE2
Erbitux MEtastatic Colorectal Cancer Strategy Study
- Status
- COMPLETED
- Phase
- PHASE3
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
- Status
- COMPLETED
- Phase
- PHASE3
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
- Status
- COMPLETED
- Phase
- NA
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
- Status
- TERMINATED
- Phase
- PHASE2
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
- Status
- UNKNOWN
- Phase
- PHASE2
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2